Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
Rajeshwari Sridhara(Center for Drug Evaluation and Research), Cindy Lu(Biogen (United States)), Yuan Li Shen, Lorenzo Hess, Scott Berry(Queen's University), Qi Jiang(National Cancer Centre Japan), Olga Marchenko(Yaroslav Mudryi National Law University), Mary W. Redman(Fred Hutch Cancer Center), Kit C. B. Roes(Radboud University Nijmegen), Richard Pazdur(United States Food and Drug Administration), Andrew Raven, Khadija Rantell, Marc R. Theoret(United States Food and Drug Administration), Thomas Gwise(United States Food and Drug Administration), Yuan Ji(Chicago Department of Public Health), Richard H. Simon(University of Michigan), Martin Posch(Medical University of Vienna)
Cited by 35
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k